LION bioscience Builds Chemistry R&D Center of Excellence in San Diego For Software Development and Drug Discovery

Three Key Executives Hired to Accelerate Development of Enterprise-wide

Knowledge Management Solution



Apr 04, 2001, 01:00 ET from LION bioscience

    HEIDELBERG, Germany, April 4 /PRNewswire/ --
 LION bioscience (Nasdaq:   LEON; Neuer Markt: LIO, WKN 504 350) today announced
 it has restructured its San Diego operation to accelerate the integration of
 its life science informatics expertise gained through the acquisition of Trega
 Biosciences, Inc. into the existing LION organization.  LION will focus on
 creating an R&D center of excellence in San Diego with extensive knowledge in
 chemistry, medicinal chemistry and computational sciences.  This R&D center
 will develop predictive software tools for ADME (Absorption, Distribution,
 Metabolism and Excretion), toxicology and build novel software solutions for
 cheminformatics in accordance with LION's goal to revolutionize the way
 information technology driven drug discovery is conducted in the future.  It
 will also support LION's internal drug discovery program, iD3(TM).  This
 integration is expected to strongly support the establishment of LION's
 integrated horizontal enterprise-wide information and knowledge management
 solutions -- which combine biology, chemistry and preclinical research with
 clinical and individual data and information -- as the standard in the market.
 As part of this restructuring, LION will reduce Trega's current workforce by
 approximately 20%.
     This integration process will be driven by three new key executives, each
 with between 10 and 20 years of industry experience, who have joined LION from
 MDL Information Systems Inc., a leading provider in the field of
 cheminformatics.  Joining LION are: Rudolph Potenzone, Ph.D. as President and
 Chief Executive Officer of LION's U.S. operations, Daniel Keesman, Ph.D. as
 Vice President Global Sales & Marketing, and Mark Canales, Ph.D. as Senior
 Vice President Cheminformatics Development.  Dr. Potenzone replaces Michael G.
 Grey who has resigned from his position as Chief Executive Officer and
 President of Trega.
     This newly acquired expertise in chemistry and medicinal chemistry
 augments LION's already strong expertise in biology, increasing its
 applicability across the entire R&D chain.  Through the recent merger with
 Trega, and the cooperation with the Gesellschaft fur Medizinische
 Datenverarbeitung (GMD), announced in February 2001, LION has gained direct
 access to complimentary software in the preclinical and clinical fields.  This
 range of application modules together with LION's integration platform SRS,
 spanning the entire R&D process of the life science industry, forms the
 foundation for LION's horizontal, enterprise-wide IT-solutions for the life
 sciences industry, called i-biology(R).  These solutions fully support and
 leverage the users' R&D capabilities and have the potential to significantly
 accelerate genome-based drug discovery and development.
     "Our recent acquisition of Trega as well as our alliances with GMD,
 Tripos, Inc. and Paradigm Genetics have enabled us to further build and offer
 comprehensive, horizontally-integrated solutions to meet and support the
 increasing demands of the Life Sciences industry," said Dr. Friedrich von
 Bohlen, CEO of LION.  "With the appointments of Drs. Potenzone, Keesman and
 Canales, LION gains recognized experts and managers in the field of chemistry
 and cheminformatics.  Their business experience will allow us to more quickly
 extend our established in-house expertise in information solutions from
 biology into preclinical research.  As a result, we expect to more rapidly
 attain our goal of establishing i-biology(R) as the standard knowledge
 management solution in the marketplace."
     LION's activities in cheminformatics started in 1998.  In October 2000,
 LION entered into a landmark $25M pharmacophore arrangement with Bayer
 pursuant to which LION -- together with Tripos -- is implementing a novel
 pharmacophore informatics prediction platform for Bayer on a worldwide basis.
 The recent merger with Trega has extended LION's in-house expertise into the
 area of medicinal chemistry, chemical libraries and predictive software for
 ADME/toxicology.  The appointments of Drs. Potenzone, Keesman and Canales
 underline LION's long-term objective to provide horizontally-integrated,
 enterprise-wide information systems to accelerate and improve R&D quality and
 performance.
     Dr. Rudolph Potenzone, formerly Senior Vice President for Marketing &
 Development at MDL, heads LION's U.S. operations.  With more than 20 years of
 cheminformatics experience, Potenzone most recently worked at MDL where he
 managed the design, development and marketing of the company's software and
 database products.  Previously, Dr. Potenzone was Director of Research and New
 Product Development at Chemical Abstracts Service (CAS), and, prior to CAS, at
 Polygen/Molecular Simulations, Inc. Dr. Potenzone brings over ten years of
 industrial experience managing chemical information systems.  He holds a Ph.D.
 in macromolecular science from Case Western Reserve University in Cleveland,
 Ohio and a bachelor of science degree in biophysics and microbiology from the
 University of Pittsburgh.
     Dr. Daniel Keesman has been appointed as Global Vice President, Sales &
 Marketing for LION bioscience, Inc.  While at MDL, he served as Vice President
 for MDL Europe and Managing Director of MDL Frankfurt, responsible for all of
 MDL's operations and business within Europe.  Previously, he had served in
 different positions at MDL, including as Director of Professional Services
 Europe, in charge of the implementation of multi-national projects for
 Discovery Informatics.  He received his Ph.D. and diploma in chemistry from
 the University of Stuttgart.  In his new position at LION, Dr. Keesman will be
 responsible for directing LION's business strategy and initiatives and for
 leading LION's sales and services organization.  He will be based in
 Heidelberg, Germany.
     Dr. Mark Canales, formerly Vice President of Product Development at MDL,
 has been appointed as Senior Vice President Cheminformatics Development for
 LION's U.S. operations.  Dr. Canales will be responsible for integrating
 cheminformatics product development with bioinformatics product development at
 LION.  Dr. Canales has over 17 years experience in the design and development
 of software and hardware solutions for the scientific market.  He has
 successfully managed multiple projects with multinational development groups
 spread across multiple sites.  In the past, Dr. Canales also acted as director
 of product development at ThermoQuest Corporation's Finnigan Corporation
 subsidiary.  Prior to joining Finnigan, Dr. Canales worked with PE Nelson
 Systems (formerly Nelson Analytical) where he led both software and hardware
 programs within the Desktop DataSystems Group.  Dr. Canales holds a Ph.D. in
 biochemistry from the University of Minnesota.  His undergraduate degrees are
 an A.B. in philosophy and B.S. in chemistry from Gonzaga University.
 
     About Cheminformatics:
     Cheminformatics involves the combination of chemistry and computation, and
 is the management of data, information and knowledge of chemical compounds and
 their measured properties, such as biological activity.  When used in drug
 discovery, it helps chemists choose which new compounds should be synthesized
 from the almost infinite number of possible molecular structures.
 Cheminformatics advances are playing an essential role in generating,
 selecting and optimizing qualified drug leads from the increasing amount of
 potential drug targets.
 
     About LION bioscience AG:
     LION bioscience (http://www.lionbioscience.com) provides proven
 information and knowledge management solutions to significantly improve life
 science R&D performance and productivity. These solutions integrate all R&D
 disciplines, spanning from genetics to early and late discovery through
 clinical trials.  LION offers these solutions via two primary lines of
 business:
     -- i-biology(R): the installation and implementation of enterprise-wide
        horizontal information and knowledge management solutions as part of
        LION's Life Science Informatics (LSI(TM)) line of business; and
     -- Integrated Drug Discovery and Diagnostics (iD3(TM)): application of
        i-biology(R) to LION's internal drug discovery program with the goal to
        out-license specific databases, polymorphism marker panels, and
        validated targets and leads.
 
     Founded in 1997, LION, together with its consolidated subsidiaries, has
 more than 440 employees, with headquarters in Heidelberg, Germany, and
 subsidiaries in Cambridge, UK, Cambridge, MA, USA, and as a result of the
 Trega acquisition, San Diego, CA, USA.  To date, LION has established
 partnerships with leading life science companies, including Aventis, Bayer,
 Boehringer Ingelheim, Celera, DuPont, Glaxo Wellcome, GMD, Janssen, Merck
 Inc., Nestle, Novartis, Paradigm Genetics, Pharmacia & Upjohn, Roche,
 SmithKline Beecham, Sumitomo Pharmaceuticals and Tripos.
 
     All statements in this press release that are not historical are
 forward-looking statements within the meaning of the U.S. securities laws.
 Such statements are based on current expectations that are subject to risks
 and uncertainties.  Actual results may vary materially from those projected
 because of factors such as uncertainties relating to technologies, product
 development, or manufacturing, market acceptance, cost or pricing of LION's
 products, dependence on collaborations and partners, regulatory approvals,
 competition, intellectual property of others, or patent protection and
 litigation.  These and other risk factors are discussed in LION's Registration
 Statement on Form F-4 declared effective by the SEC on February 9, 2001.  LION
 expressly disclaims any obligation or undertaking to release publicly any
 updates, revisions or corrections to any forward-looking statements or
 historical information contained herein.
     LION bioscience(R), SRS, SRS 6.1 and i-biology(R) are either registered
 trademarks of LION bioscience AG in the United States and/or other countries,
 or LION bioscience AG has pending applications for these trademarks in the
 United States and/or other countries.  The names of other actual companies and
 products mentioned herein may be the trademark of their respective owners.
 Trega Biosciences, Inc. has a pending trademark application for iDEA(TM) in
 the United States.  Trega(R) is a registered trademark of Trega Biosciences,
 Inc.
 
     CONTACT:
 
     LION bioscience
     Dr. Andrea Kreisselmeier
     Director Corporate Marketing & Communications
     +49 (0)6221-4038 265
     andrea.kreisselmeier@lionbioscience
 
     Noonan/Russo Communications
     Matthew Scampoli
     +1 212-696-4455 ext. 243
     m.scampoli@noonanrusso.com
 
 

SOURCE LION bioscience
    HEIDELBERG, Germany, April 4 /PRNewswire/ --
 LION bioscience (Nasdaq:   LEON; Neuer Markt: LIO, WKN 504 350) today announced
 it has restructured its San Diego operation to accelerate the integration of
 its life science informatics expertise gained through the acquisition of Trega
 Biosciences, Inc. into the existing LION organization.  LION will focus on
 creating an R&D center of excellence in San Diego with extensive knowledge in
 chemistry, medicinal chemistry and computational sciences.  This R&D center
 will develop predictive software tools for ADME (Absorption, Distribution,
 Metabolism and Excretion), toxicology and build novel software solutions for
 cheminformatics in accordance with LION's goal to revolutionize the way
 information technology driven drug discovery is conducted in the future.  It
 will also support LION's internal drug discovery program, iD3(TM).  This
 integration is expected to strongly support the establishment of LION's
 integrated horizontal enterprise-wide information and knowledge management
 solutions -- which combine biology, chemistry and preclinical research with
 clinical and individual data and information -- as the standard in the market.
 As part of this restructuring, LION will reduce Trega's current workforce by
 approximately 20%.
     This integration process will be driven by three new key executives, each
 with between 10 and 20 years of industry experience, who have joined LION from
 MDL Information Systems Inc., a leading provider in the field of
 cheminformatics.  Joining LION are: Rudolph Potenzone, Ph.D. as President and
 Chief Executive Officer of LION's U.S. operations, Daniel Keesman, Ph.D. as
 Vice President Global Sales & Marketing, and Mark Canales, Ph.D. as Senior
 Vice President Cheminformatics Development.  Dr. Potenzone replaces Michael G.
 Grey who has resigned from his position as Chief Executive Officer and
 President of Trega.
     This newly acquired expertise in chemistry and medicinal chemistry
 augments LION's already strong expertise in biology, increasing its
 applicability across the entire R&D chain.  Through the recent merger with
 Trega, and the cooperation with the Gesellschaft fur Medizinische
 Datenverarbeitung (GMD), announced in February 2001, LION has gained direct
 access to complimentary software in the preclinical and clinical fields.  This
 range of application modules together with LION's integration platform SRS,
 spanning the entire R&D process of the life science industry, forms the
 foundation for LION's horizontal, enterprise-wide IT-solutions for the life
 sciences industry, called i-biology(R).  These solutions fully support and
 leverage the users' R&D capabilities and have the potential to significantly
 accelerate genome-based drug discovery and development.
     "Our recent acquisition of Trega as well as our alliances with GMD,
 Tripos, Inc. and Paradigm Genetics have enabled us to further build and offer
 comprehensive, horizontally-integrated solutions to meet and support the
 increasing demands of the Life Sciences industry," said Dr. Friedrich von
 Bohlen, CEO of LION.  "With the appointments of Drs. Potenzone, Keesman and
 Canales, LION gains recognized experts and managers in the field of chemistry
 and cheminformatics.  Their business experience will allow us to more quickly
 extend our established in-house expertise in information solutions from
 biology into preclinical research.  As a result, we expect to more rapidly
 attain our goal of establishing i-biology(R) as the standard knowledge
 management solution in the marketplace."
     LION's activities in cheminformatics started in 1998.  In October 2000,
 LION entered into a landmark $25M pharmacophore arrangement with Bayer
 pursuant to which LION -- together with Tripos -- is implementing a novel
 pharmacophore informatics prediction platform for Bayer on a worldwide basis.
 The recent merger with Trega has extended LION's in-house expertise into the
 area of medicinal chemistry, chemical libraries and predictive software for
 ADME/toxicology.  The appointments of Drs. Potenzone, Keesman and Canales
 underline LION's long-term objective to provide horizontally-integrated,
 enterprise-wide information systems to accelerate and improve R&D quality and
 performance.
     Dr. Rudolph Potenzone, formerly Senior Vice President for Marketing &
 Development at MDL, heads LION's U.S. operations.  With more than 20 years of
 cheminformatics experience, Potenzone most recently worked at MDL where he
 managed the design, development and marketing of the company's software and
 database products.  Previously, Dr. Potenzone was Director of Research and New
 Product Development at Chemical Abstracts Service (CAS), and, prior to CAS, at
 Polygen/Molecular Simulations, Inc. Dr. Potenzone brings over ten years of
 industrial experience managing chemical information systems.  He holds a Ph.D.
 in macromolecular science from Case Western Reserve University in Cleveland,
 Ohio and a bachelor of science degree in biophysics and microbiology from the
 University of Pittsburgh.
     Dr. Daniel Keesman has been appointed as Global Vice President, Sales &
 Marketing for LION bioscience, Inc.  While at MDL, he served as Vice President
 for MDL Europe and Managing Director of MDL Frankfurt, responsible for all of
 MDL's operations and business within Europe.  Previously, he had served in
 different positions at MDL, including as Director of Professional Services
 Europe, in charge of the implementation of multi-national projects for
 Discovery Informatics.  He received his Ph.D. and diploma in chemistry from
 the University of Stuttgart.  In his new position at LION, Dr. Keesman will be
 responsible for directing LION's business strategy and initiatives and for
 leading LION's sales and services organization.  He will be based in
 Heidelberg, Germany.
     Dr. Mark Canales, formerly Vice President of Product Development at MDL,
 has been appointed as Senior Vice President Cheminformatics Development for
 LION's U.S. operations.  Dr. Canales will be responsible for integrating
 cheminformatics product development with bioinformatics product development at
 LION.  Dr. Canales has over 17 years experience in the design and development
 of software and hardware solutions for the scientific market.  He has
 successfully managed multiple projects with multinational development groups
 spread across multiple sites.  In the past, Dr. Canales also acted as director
 of product development at ThermoQuest Corporation's Finnigan Corporation
 subsidiary.  Prior to joining Finnigan, Dr. Canales worked with PE Nelson
 Systems (formerly Nelson Analytical) where he led both software and hardware
 programs within the Desktop DataSystems Group.  Dr. Canales holds a Ph.D. in
 biochemistry from the University of Minnesota.  His undergraduate degrees are
 an A.B. in philosophy and B.S. in chemistry from Gonzaga University.
 
     About Cheminformatics:
     Cheminformatics involves the combination of chemistry and computation, and
 is the management of data, information and knowledge of chemical compounds and
 their measured properties, such as biological activity.  When used in drug
 discovery, it helps chemists choose which new compounds should be synthesized
 from the almost infinite number of possible molecular structures.
 Cheminformatics advances are playing an essential role in generating,
 selecting and optimizing qualified drug leads from the increasing amount of
 potential drug targets.
 
     About LION bioscience AG:
     LION bioscience (http://www.lionbioscience.com) provides proven
 information and knowledge management solutions to significantly improve life
 science R&D performance and productivity. These solutions integrate all R&D
 disciplines, spanning from genetics to early and late discovery through
 clinical trials.  LION offers these solutions via two primary lines of
 business:
     -- i-biology(R): the installation and implementation of enterprise-wide
        horizontal information and knowledge management solutions as part of
        LION's Life Science Informatics (LSI(TM)) line of business; and
     -- Integrated Drug Discovery and Diagnostics (iD3(TM)): application of
        i-biology(R) to LION's internal drug discovery program with the goal to
        out-license specific databases, polymorphism marker panels, and
        validated targets and leads.
 
     Founded in 1997, LION, together with its consolidated subsidiaries, has
 more than 440 employees, with headquarters in Heidelberg, Germany, and
 subsidiaries in Cambridge, UK, Cambridge, MA, USA, and as a result of the
 Trega acquisition, San Diego, CA, USA.  To date, LION has established
 partnerships with leading life science companies, including Aventis, Bayer,
 Boehringer Ingelheim, Celera, DuPont, Glaxo Wellcome, GMD, Janssen, Merck
 Inc., Nestle, Novartis, Paradigm Genetics, Pharmacia & Upjohn, Roche,
 SmithKline Beecham, Sumitomo Pharmaceuticals and Tripos.
 
     All statements in this press release that are not historical are
 forward-looking statements within the meaning of the U.S. securities laws.
 Such statements are based on current expectations that are subject to risks
 and uncertainties.  Actual results may vary materially from those projected
 because of factors such as uncertainties relating to technologies, product
 development, or manufacturing, market acceptance, cost or pricing of LION's
 products, dependence on collaborations and partners, regulatory approvals,
 competition, intellectual property of others, or patent protection and
 litigation.  These and other risk factors are discussed in LION's Registration
 Statement on Form F-4 declared effective by the SEC on February 9, 2001.  LION
 expressly disclaims any obligation or undertaking to release publicly any
 updates, revisions or corrections to any forward-looking statements or
 historical information contained herein.
     LION bioscience(R), SRS, SRS 6.1 and i-biology(R) are either registered
 trademarks of LION bioscience AG in the United States and/or other countries,
 or LION bioscience AG has pending applications for these trademarks in the
 United States and/or other countries.  The names of other actual companies and
 products mentioned herein may be the trademark of their respective owners.
 Trega Biosciences, Inc. has a pending trademark application for iDEA(TM) in
 the United States.  Trega(R) is a registered trademark of Trega Biosciences,
 Inc.
 
     CONTACT:
 
     LION bioscience
     Dr. Andrea Kreisselmeier
     Director Corporate Marketing & Communications
     +49 (0)6221-4038 265
     andrea.kreisselmeier@lionbioscience
 
     Noonan/Russo Communications
     Matthew Scampoli
     +1 212-696-4455 ext. 243
     m.scampoli@noonanrusso.com
 
 SOURCE  LION bioscience